Biology, treatment, and time

摘要

Total therapy 2 (TT2) was a randomized prospective treatment trial composed of a complex regimen (induction, 2 autologous peripheral blood stem cell transplantations [ASCTs], consolidative chemotherapy, and maintenance) given with or without thalido-mide during all phases of treatment. In their original report with 42 months' follow-up, the higher complete response and event-free survival rates enjoyed by patients on the thalidomide arm had not translated into superior OS. However, in the current paper at 72 months' follow-up, a distinct survival advantage was seen for the 30% of patients with abnormal cytogenetics